Oral factor Xa inhibitor underutilization following lower extremity peripheral vascular intervention.

ABSTRACT:

Objective

Patients undergoing peripheral vascular intervention (PVI) (ie, endovascular revascularization) for symptomatic lower extremity peripheral artery disease remain at high risk for major adverse limb and cardiovascular events. High-quality evidence demonstrates the addition of a low-dose oral factor Xa inhibitor to single antiplatelet therapy, termed dual pathway inhibition (DPI), reduces the incidence of major adverse events in this population. This study aims to describe the longitudinal trends in factor Xa inhibitor initiation after PVI, identify patient and procedural characteristics associated with factor Xa inhibitor use, and describe temporal trends in antithrombic therapy post-PVI before vs after VOYAGER PAD.

Methods

This retrospective cross-sectional study wa

SUBMITTER: Bhuta S 

PROVIDER: S-EPMC10524143 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature